MM

BeyondSpring and Leading Cancer Center Present Poster Highlighting Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCT

Retrieved on: 
Wednesday, June 7, 2023
Neutropenia, Platelet transfusion, RBC, IV, Multiple myeloma, Pegfilgrastim, Fever, Assistant, MS, ASCO, American Society of Clinical Oncology, Patient, Memorial Sloan Kettering Cancer Center, Annual general meeting, Drug discovery, MM, MSK, Toxic leukoencephalopathy, Principal, Melphalan, Society, Pharmaceutical industry, Blood product, MD, Plinabulin

BeyondSpring and Memorial Sloan Kettering Cancer Center (MSK) presented the data at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting .

Key Points: 
  • BeyondSpring and Memorial Sloan Kettering Cancer Center (MSK) presented the data at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting .
  • Between January 2022 and February 2023, 15 patients with a median age of 64 received Plinabulin after a high dose of melphalan.
  • The Plinabulin and pegfilgrastim combination appears well tolerated without additional major toxicities post AHCT.
  • “The Plinabulin-pegfilgrastim combination represents a new potential supportive care for MM patients undergoing AHCT.

IASO Bio and Innovent Updated Efficacy and Safety Clinical Data of Equecabtagene Autoleucel（BCMA CAR-T Cell Therapy）for Multiple Myeloma at the 2023 ASCO Annual Meeting

Retrieved on: 
Monday, June 5, 2023
Tongji Hospital station, DNA, Fragment crystallizable region, Pi, Biotechnology, SCR, CRS, Hook effect, DOR, B-cell maturation antigen, American Society of Clinical Oncology, Bone marrow, Huachung University, Cmax, Doctor of Philosophy, PFS, Trial of the century, MTTR, ASCO, MRD, CAR, Tongji Medical College, CR, Congress, Multiple myeloma, MD, Patient, Cytokine release syndrome, SAN, EMM, Annual general meeting, Immunotherapy, EHA, MM, RRMM, Huazhong University of Science and Technology, Proteasome inhibitor, Society, ADA, ORR, BCMA, Safety, Center for Innovative Phage Applications and Therapeutics, Disease, Vaccine, Pharmaceutical industry

The updated data showed long-term follow-up efficacy and safety of the phase 1b/2 study (FUMANBA-1) conducted in 14 centers in China.

Key Points: 
  • The updated data showed long-term follow-up efficacy and safety of the phase 1b/2 study (FUMANBA-1) conducted in 14 centers in China.
  • Among the 103 patients, 68.9% (71/103) had high-risk cytogenetic abnormalities per mSMART 3.0, 12.6%（13/103）had extramedullary multiple myeloma (EMM), and 11.7%（12/103）had received prior CAR-T therapy.
  • Equecabtagene Autoleucel demonstrated a favorable and manageable safety profile: Among the 103 patients, 93.2% (96/103) experienced cytokine release syndrome (CRS).
  • These results are encouraging and entails an opportunity to advance Equecabtagene Autoleucel to earlier lines of treatment to benefit more MM patients."

Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer

Retrieved on: 
Friday, June 2, 2023
Therapy, European Hematology Association, Genetics, ALL, DLBCL, Multiple myeloma, NGS, American Society of Clinical Oncology, Clinical trial, PFS, B-cell lymphoma, ASCO, MRD, Acute leukemia, Hematological Cancer Research Investment and Education Act, Patient, Physician, Data, Flow cytometry, Annual general meeting, EHA, ADPT, MM, Poster, Neoplasm, MASTER, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Food, Pharmaceutical industry, Medical imaging

SEATTLE, June 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, will be included in several oral and poster presentations investigating the clinical significance of minimal residual disease (MRD) assessment at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6 in Chicago, as well as the European Hematology Association (EHA) Hybrid Congress taking place June 8-11 in Frankfurt, Germany. Data will be presented from clinical trials and real-world evidence studies using Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay for MRD assessment across a range of hematologic cancers.

Key Points: 
  • Data will be presented from clinical trials and real-world evidence studies using Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay for MRD assessment across a range of hematologic cancers.
  • “Adaptive has demonstrated the value of NGS-MRD assessment in hematologic cancers.
  • This assessment is performed as a series of tests in clinical trials and throughout a patient’s cancer journey.
  • Data continues to show the potential for MRD assessment to help in the personalization of cancer care.

Mutual Holding Company for TFS Financial Corporation to Seek Member Approval for Dividend Waivers

Retrieved on: 
Thursday, June 1, 2023
Banking, Professional Services, Finance, Third Federal S&L, Failure, Federal, Parent, Structure of the Federal Reserve System, MHC, American Dream, Trust, Federal Reserve, TFS, Annual report, Love, Bloomberg L.P. v. Board of Governors of the Federal Reserve System, MM, Security (finance), News, Holding company, Bank

TFS Financial Corporation (Nasdaq: TFSL), (the “Company”), the holding company for Third Federal Savings and Loan Association of Cleveland, announced that Third Federal Savings and Loan Association of Cleveland, MHC, (the “MHC”), the mutual holding company that owns 81.0% of the Company’s outstanding common stock, will hold a special meeting of its members.

Key Points: 
  • TFS Financial Corporation (Nasdaq: TFSL), (the “Company”), the holding company for Third Federal Savings and Loan Association of Cleveland, announced that Third Federal Savings and Loan Association of Cleveland, MHC, (the “MHC”), the mutual holding company that owns 81.0% of the Company’s outstanding common stock, will hold a special meeting of its members.
  • All dividends on the Company’s common stock are declared at the discretion of the Company’s Board of Directors.
  • A failure to obtain the waiver will likely result in a reduction in the dividend expected to be paid to public stockholders.
  • The Company undertakes no responsibility to publicly update or revise any forward-looking statement.

FCM Concerned MindMed’s Mismanagement Threatens Mental Health for Millions

Retrieved on: 
Thursday, May 25, 2023
BLUE, Drug development, FOR, Biotechnology, Clinical trial, LSD, CMO, Central nervous system, Plasma protein binding, SEDAR, MM, Security (finance), FDA, NOW, MindMed, FCM, Pharmaceutical industry

SHERIDAN, Wyo., May 25, 2023 (GLOBE NEWSWIRE) -- FCM MM Holdings, LLC ("FCM"), today announced that it published a presentation outlining the overwhelming case for change at Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (“MindMed”, the “Company”) and how to efficiently bring much needed mental health drugs to millions with mental health disorders amid MindMed’s announcements of clinical trial delays.

Key Points: 
  • SHERIDAN, Wyo., May 25, 2023 (GLOBE NEWSWIRE) -- FCM MM Holdings, LLC ("FCM"), today announced that it published a presentation outlining the overwhelming case for change at Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (“MindMed”, the “Company”) and how to efficiently bring much needed mental health drugs to millions with mental health disorders amid MindMed’s announcements of clinical trial delays.
  • In our view, this irresponsible spending behavior and mismanagement has jeopardized bringing needed treatment for mental health disorders as evidenced by the LSD (MM-120) trial delays and the shuttering of MM-110.
  • “I co-founded MindMed to help millions of people with mental health disorders.
  • MindMed recently hired Greenleaf Health, Inc. (“Greenleaf”), a paid consulting firm, to support MindMed’s agenda and discredit FCM’s proposals.

International Myeloma Foundation to Host 2023 Global Myeloma Action Network (GMAN) Summit in Frankfurt 

Retrieved on: 
Thursday, May 25, 2023
Czech Republic, NCT, Myeloma Canada, Committee, Hospital, MD, Patient, European, MM, IMF, Disease, National Center for Healthcare Leadership, Executive, Comp 175: A Benefit for Queer Programs and Services in the Pacific Northwest, Protocol, Clinical trial, Service, Multiple myeloma, Policy, Hope, Human, Research, CNN International Europe/Middle East/Africa, Organization, Knowledge, Empowerment, SEE, Canada, SND, International Myeloma Foundation, CTS, Medicine, Gold, University Hospital Heidelberg, Education, Quality of life, Germany, Nursing, Pharmaceutical industry, Management, Risk management, Fine chemical, Renewable energy, Health care, EU, Beer

LOS ANGELES, May 25, 2023 (GLOBE NEWSWIRE) -- Founded in 2013 by the International Myeloma Foundation (IMF), the Global Myeloma Action Network (GMAN) will hold its Annual Summit in Frankfurt Germany, from June 2-4, 2023.

Key Points: 
  • LOS ANGELES, May 25, 2023 (GLOBE NEWSWIRE) -- Founded in 2013 by the International Myeloma Foundation (IMF), the Global Myeloma Action Network (GMAN) will hold its Annual Summit in Frankfurt Germany, from June 2-4, 2023.
  • "While multiple myeloma continues to be an incurable disease, we have made remarkable progress in improving patient outcomes and quality of life.
  • “Over the past 10 years, GMAN had a significant increase in attendance of myeloma advocates from different countries.
  • During the 2022 GMAN Summit in Milan, our global network reached 42 myeloma organizations from 39 countries in 5 continents.

Jana Partners Calls on Freshpet Board to Immediately Rectify Highly Entrenching Actions Intended to Disenfranchise Shareholders and Manipulate Shareholder Vote

Retrieved on: 
Thursday, May 25, 2023
Professional Services, Consumer, Finance, Pets, Consulting, Banking, Benchmark, Exercise, Certificate, Widener University Delaware Law School, File, Face, Class, Liquid Audio, Annual, Annual Meetings of the International Monetary Fund and the World Bank Group, Blasius, Falls, JANA, Atlantic Reporter, Annual general meeting, Form, MM, Del, Freshpet, III, Financial adviser, Management, Holding company, By-law

JANA hereby demands that the Board immediately remedy those breaches.

Key Points: 
  • JANA hereby demands that the Board immediately remedy those breaches.
  • Thus, for months the Board has been aware of JANA’s intent to contest the election of the four Class III directors up for election at the 2023 Annual Meeting.
  • Indeed, as you likely are aware, in the days leading up to the Board’s recent actions, JANA and the Board engaged in discussions about appointing individuals proposed by JANA to the Board.
  • 2003) (invalidating board expansion undertaken “for the primary purpose of diminishing the influence of [insurgent’s] two nominees on a five-member Board”).

Healthcare Administrative Hub, Dock Health, Secures $5M in Funding Led by MassMutual with Participation from DaVita Venture Group and August Capital

Retrieved on: 
Thursday, May 25, 2023
Software, Managed Care, Professional Services, Data Management, Venture Capital, Apps, Applications, Technology, Artificial Intelligence, Health Technology, Data Analytics, Practice Management, Health, August Capital, Investment, MMCF, Multimedia, Electronic health record, Organization, MassMutual, Friction, Patient, DaVita Inc., MM, Growth, Hospital, AI, API, Automation, Warehouse, Nursing, Dock

Dock Health, Inc., the administrative hub for healthcare professionals, today announced $5 million in funding led by MassMutual through its MM Catalyst Fund (MMCF) with participation from DaVita Venture Group and initial seed investor, August Capital.

Key Points: 
  • Dock Health, Inc., the administrative hub for healthcare professionals, today announced $5 million in funding led by MassMutual through its MM Catalyst Fund (MMCF) with participation from DaVita Venture Group and initial seed investor, August Capital.
  • View the full release here: https://www.businesswire.com/news/home/20230525005254/en/
    Dock Health: HIPAA-compliant task management and workflow automation together in the only administrative hub for healthcare.
  • Administrative best practices community: Thousands of healthcare providers use Dock every day to help keep healthcare moving forward.
  • Dock Health is a HIPAA-compliant workflow management platform “For The Other Half Of Healthcare” -- the administrative side of care delivery.

Humble & Fume Inc. Announces Financial Results for Third Quarter Fiscal 2023

Retrieved on: 
Thursday, May 11, 2023
CSE, Humble, Bank statement, Stock, Collection, SEDAR, MM, Cannabis, Growth, AR, Retail, Management, Risk management, Q3

TORONTO, May 11, 2023 /PRNewswire/ - Humble & Fume Inc. (CSE: HMBL) (OTCQX: HUMBF) ("Humble" or the "Company"), a leading distributor of cannabis and cannabis accessories in North America, announced its financial and operating results for the third quarter of fiscal 2023 ended March 31, 2023.

Key Points: 
  • TORONTO, May 11, 2023 /PRNewswire/ - Humble & Fume Inc. (CSE: HMBL) (OTCQX: HUMBF) ("Humble" or the "Company"), a leading distributor of cannabis and cannabis accessories in North America, announced its financial and operating results for the third quarter of fiscal 2023 ended March 31, 2023.
  • The Company made significant progress toward achieving its goals and recorded several improvements in its operations, including reduced operating expenses and increased gross margins.
  • The Company also upgraded talent and promoted functional experts within the business, resulting in improved commercial performance reporting and strengthened financial controls.
  • The financial statements, notes to the financial statements, and Management's Discussion and Analysis for the nine and three months ended March 31, 2023, are available on the SEDAR website at www.sedar.com .

2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023

Retrieved on: 
Thursday, May 11, 2023
Oncology, Health, General Health, Clinical Trials, Research, Science, Biotechnology, Abstract, Pros, European Hematology Association, Multiple myeloma, TCE, American Society of Clinical Oncology, RCT, Spectroscopy, Trial of the century, ASCO, Congress, CAR, Patient, Risk, Randomized controlled trial, Quality of life (healthcare), EHA, Annual general meeting, MM, RRMM, Society, Pharmaceutical industry, Nursing, Idecabtagene vicleucel

The presentations will highlight clinical and correlative data from the KarMMa-2 and KarMMa-3 clinical trials evaluating Abecma (idecabtagene vicleucel) in patients with relapsed and/or refractory multiple myeloma (RRMM) or newly diagnosed multiple myeloma.

Key Points: 
  • The presentations will highlight clinical and correlative data from the KarMMa-2 and KarMMa-3 clinical trials evaluating Abecma (idecabtagene vicleucel) in patients with relapsed and/or refractory multiple myeloma (RRMM) or newly diagnosed multiple myeloma.
  • “These data highlight the growing body of evidence that further support the value of Abecma across various subgroups of patients with triple-class-exposed relapsed and/or refractory multiple myeloma, who, despite recent advancements, still need more effective treatment options sooner,” said Steve Bernstein, M.D., chief medical officer, 2seventy bio.
  • Additional analysis of outcomes by number of prior lines of therapy from the KarMMa-3 clinical trial showcasing the use of Abecma in patients who received two to four prior lines of therapy.
  • Patient-reported outcomes from the pivotal Phase 3 KarMMa-3 trial in patients with triple-class exposed RRMM treated with Abecma versus standard regimens.